Hassan: 55 million pounds are investments for the “Insulin Pens” project this year
The Danish pharmaceutical company, Novonordisk, aims to achieve sales of 1.2 billion pounds by the end of this year, with a growth rate of 10%.
Ayman Hassan, General Manager of Novo Nordisk Egypt, said that the company achieved sales of 1.1 billion pounds during the year 2020, ranking 17th among the best-selling companies in the Egyptian market.
Hassan added that the company plans to invest EGP 55 million this year in the insulin pens project for treating diabetes.
Novonordisk International is present in 170 countries, it produces about 50% of the insulin for treating diabetes in the world and annually invests about two billion euros in research.
Today, Thursday, the company held a press conference to announce a study on the burdens related to obesity in Egypt and the launch of the drug “Saxenda 3 mg” to treat obesity and overweight diseases, and the consequent diseases such as heart disease, diabetes, high blood pressure, cholesterol and others.
Hassan said that Novonordisk Egypt’s launch of the new drug comes in parallel with the Egyptian state’s orientation and its national campaign of 100 million health to eliminate obesity, anemia and stunting.
According to the results of the 100 Million Health Campaign survey, it was found that the rate of obesity, obesity and overweight in Egypt reaches 75%, while global rates reach less than that.
The study indicated that obesity costs Egyptians about 50 billion pounds annually to treat the associated diseases, and this figure includes direct medical costs for treating patients who suffer from these diseases due to obesity.
The article “Novonordisk Pharmaceuticals” targeting 1.2 billion pounds sales by the end of 2021 was written in the Al-Borsa newspaper.